April 10 (Reuters) - Bristol-Myers Squibb Co :
   * NEOADJUVANT OPDIVO (NIVOLUMAB) PLUS CHEMOTHERAPY SIGNIFICANTLY IMPROVES PATHOLOGIC COMPLETE RESPONSE IN PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER IN PHASE 3 CHECKMATE -816 TRIAL
   * BRISTOL-MYERS SQUIBB - NEARLY A QUARTER OF PATIENTS WHO RECEIVED OPDIVO PLUS CHEMOTHERAPY SHOWED NO EVIDENCE OF CANCER CELLS IN TISSUE REMOVED
   * BRISTOL-MYERS SQUIBB - OPDIVO PLUS CHEMOTHERAPY WAS WELL TOLERATED; SHOWED CONSISTENT IMPROVEMENTS IN PCR
   * BRISTOL-MYERS SQUIBB - OPDIVO PLUS CHEMOTHERAPY ALSO DEMONSTRATED IMPROVEMENTS IN KEY SECONDARY ENDPOINTS, INCLUDING MAJOR PATHOLOGICAL RESPONSE
   * BRISTOL-MYERS SQUIBB - THREE CYCLES OF OPDIVO PLUS CHEMOTHERAPY WERE ASSOCIATED WITH A TOLERABLE SAFETY PROFILE; NO NEW SAFETY SIGNALS WERE OBSERVED
   * SURGERY WAS RARELY CANCELED DUE TO ADVERSE EVENTS, ONLY AFFECTING TWO PATIENTS IN EACH ARM OF TRIAL
   * BRISTOL-MYERS SQUIBB - NUMBER OF PATIENTS WHOSE TUMORS WERE COMPLETELY RESECTED (R0) WAS HIGHER WITH OPDIVO PLUS CHEMOTHERAPY VERSUS. CHEMOTHERAPY
   * BRISTOL-MYERS SQUIBB - RATES OF SURGERY-RELATED ADVERSE EVENTS WERE SIMILAR BETWEEN TWO TREATMENT ARMS

Source text for Eikon:  Further company coverage:

((Reuters.Briefs@thomsonreuters.com;)